IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical
technology company focused on the development and commercialization of
novel implantable Sacral Neuromodulation (“SNM”) devices for the
treatment of urinary
and bowel dysfunction, disclosed today positive top-line results
from the ARTISAN-SNM pivotal study, designed to gain marketing approval
from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM®
The clinical study demonstrated that patients implanted with the Axonics
r-SNM System received clinically meaningful and statistically
significant improvements in Urinary Urgency Incontinence (“UUI”)
symptoms and quality of life. Additionally, the study met all secondary
endpoints. No serious device-related adverse events have been reported.
The ARTISAN-SNM study is a 129-patient single-arm, prospective,
multi-center, unblinded pivotal clinical study approved under an FDA
Investigational Device Exemption (“IDE”) to evaluate the safety and
efficacy of the Axonics r-SNM System for urinary dysfunction. The study
was conducted in 14 centers in the U.S. and 5 centers in Western Europe.
Karen Noblett, M.D., Chief Medical Officer of Axonics, commented, “This
successful clinical study marks an important milestone on our path to
gaining FDA approval. Historically, SNM therapy has only been available
with a non-rechargeable implanted neurostimulator with an average
lifespan of four years requiring replacement surgery due to depletion of
the neurostimulator battery. We believe that, in addition to reducing
costs for patients and payors, the miniaturized 5cc rechargeable Axonics
system, qualified to last in the body for at least 15 years, can
significantly increase adoption of SNM therapy.”
All patients diagnosed with UUI and meeting study criteria were
implanted with a tined lead and the Axonics neurostimulator. Efficacy
data was collected using a 3-day bladder diary, a validated quality of
life questionnaire (ICIQ-OABqol), and a satisfaction questionnaire.
Therapy responders were identified as patients with at least 50%
reduction in urgency incontinence episodes at follow up visits as
compared to baseline. An as-treated analysis was performed for all 129
At six months, 90% of all implanted patients were therapy responders
(Figure 1A) including 80% of therapy responders with a ≥75% reduction in
urgency incontinence episodes of which 34% were completely dry.
Across all patients, urgency incontinence episodes per day reduced from
5.6 ± 0.3 (mean ± standard error) at baseline to 1.3 ± 0.2 at six months
(p<0.0001; Figure 1B).
Patients averaged statistically and clinically significant improvement
on the composite ICIQ-OABqol score (34 points) at six months as compared
to baseline and 93% of all implanted patients were satisfied with their
Premarket Approval (PMA) Status with the U.S. FDA
Axonics filed a PMA application on December 3, 2018 and interim clinical
data from the ARTISAN-SNM study with the FDA at the end of 2018. The
clinical data disclosed herein has not yet been reviewed by the FDA.
Axonics intends to file the six-month clinical data with the FDA during
the week of February 18. Axonics does not anticipate that the filing of
this additional clinical data will impact the standard 180-day PMA
review timeline for the FDA to complete its review and issue a decision
Conference Call and Webcast
As previously announced, the Company will host a conference call with
the investment community to discuss 2018 fourth quarter and full-year
financial results and recent business developments, including clinical
data from the ARTISAN-SNM study, on Tuesday, March 5, 2019, at 4:30 p.m.
Interested parties may access the live call via telephone by dialing
(866) 687-5771 (U.S.) or (409) 217-8725 (International) and using
passcode 3386378. A live webcast of the call may be accessed by visiting
the Events & Presentations page of the investors section of the
Company’s website at ir.axonicsmodulation.com.
A replay of the webcast will be available shortly after the conclusion
of the call and will be archived on the Company’s website for 90 days.
About Overactive Bladder and Sacral Neuromodulation
Overactive bladder (OAB) includes urinary urge incontinence and urinary
frequency and affects an estimated 85 million adults in the U.S. and
Europe. OAB is caused by a miscommunication between the bladder and the
brain and significantly impacts quality of life. SNM therapy is a
well-established treatment that has been widely employed to reduce
symptoms and restore bladder function and is also employed to treat
urinary retention and fecal incontinence. Reimbursement for SNM is well
established in the United States and is a covered service in Europe,
Canada and Australia.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM System is the first
rechargeable Sacral Neuromodulation system approved for sale in Europe,
Canada and Australia. The r-SNM System offers a temporary disposable
external trial system and a miniaturized and rechargeable long-lived
stimulator that is qualified to function in the body for at least 15
years. Also included is a tined lead, as well as patient-friendly
accessories such as a charging system optimized for minimal charge time
without overheating, a small, easy to use patient remote control and an
intuitive clinician programmer that facilitates lead placement and
programming. For more information, visit the Company’s website at www.axonicsmodulation.com
Statements made in this press release that relate to future plans,
events, prospects or performance are forward-looking statements as
defined under the Private Securities Litigation Reform Act of 1995.
Words such as “planned,” “expects,” “believes,” “anticipates,”
“designed,” and similar words are intended to identify forward-looking
statements. While these forward-looking statements are based on the
current expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties, assumptions
and other factors that could cause actual results to differ materially
from the expectations expressed in this press release, including the
risks and uncertainties disclosed in Axonics filings with the Securities
and Exchange Commission, all of which are available online at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as required by law, Axonics undertakes no obligation to update or
revise any forward-looking statements to reflect new information,
changed circumstances or unanticipated events.
1 The Axonics r-SNM System is
currently designated as an investigational medical device
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
& Chief Financial Officer
Investor & Media Contact